HALO - Halozyme Therapeutics Non-GAAP EPS of $0.74 beats by $0.10 revenue of $221.04M beats by $21.09M

August, 08 2023 04:04 PM Halozyme Therapeutics Inc.

2023-08-08 16:04:28 ET

Halozyme Therapeutics press release ( NASDAQ: HALO ): Q2 Non-GAAP EPS of $0.74 beats by $0.10 .
Revenue of $221.04M (+45.1% Y/Y) beats by $21.09M .
Royalty Revenue Increased 31% YOY to Record $111.7 million
2023 Outlook: Total revenue of $825 million to $845 million, representing growth of 25% to 28% over 2022 total revenue primarily driven by continued strength in Wave 2 products, including DARZALEX ^® SC (daratumumab) and Phesgo ^® (pertuzumab, trastuzumab and hyaluronidase) utilizing ENHANZE ^® , as well as full year auto-injector royalty and product contribution. The Company expects revenue from royalties of $445 million to $455 million, representing growth of 23% to 26%.
EBITDA of $420 million to $440 million, representing growth of >30% over 2022. EBITDA excludes the impact of amortization costs related to the Antares Pharma acquisition.
Non-GAAP diluted earnings per share of $2.65 to $2.75, representing growth of 20% over 2022 ¹ . The Company's earnings per share guidance does not consider the impact of potential future share repurchase.

For further details see: